Protagonist Therapeutics Price to Book Ratio 2015-2022 | PTGX
Historical price to book ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The current price to book ratio for Protagonist Therapeutics as of July 01, 2022 is 1.27.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Protagonist Therapeutics Price/Book Ratio Historical Data |
Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
2022-07-01 |
7.86 |
|
1.26 |
2022-03-31 |
23.68 |
$6.22 |
3.81 |
2021-12-31 |
34.20 |
$6.27 |
5.45 |
2021-09-30 |
17.72 |
$6.92 |
2.56 |
2021-06-30 |
44.88 |
$7.52 |
5.97 |
2021-03-31 |
25.90 |
$5.90 |
4.39 |
2020-12-31 |
20.16 |
$6.39 |
3.15 |
2020-09-30 |
19.55 |
$4.54 |
4.30 |
2020-06-30 |
17.66 |
$4.55 |
3.88 |
2020-03-31 |
7.06 |
$2.28 |
3.09 |
2019-12-31 |
7.05 |
$2.94 |
2.40 |
2019-09-30 |
12.01 |
$3.51 |
3.43 |
2019-06-30 |
12.11 |
$3.38 |
3.59 |
2019-03-31 |
12.57 |
$4.31 |
2.92 |
2018-12-31 |
6.73 |
$4.85 |
1.39 |
2018-09-30 |
10.29 |
$5.14 |
2.00 |
2018-06-30 |
6.72 |
$5.07 |
1.32 |
2018-03-31 |
8.59 |
$5.42 |
1.59 |
2017-12-31 |
20.80 |
$5.72 |
3.64 |
2017-09-30 |
17.67 |
$3.41 |
5.18 |
2017-06-30 |
11.31 |
$3.61 |
3.13 |
2017-03-31 |
12.81 |
$4.45 |
2.88 |
2016-12-31 |
21.99 |
$5.24 |
4.20 |
2016-09-30 |
21.13 |
$5.83 |
3.62 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.382B |
$0.027B |
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|